NCT04308395 2024-09-24
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Terminated
Sol-Gel Technologies, Ltd.
SkinJect, Inc.
University of Arizona
Stanford University
Hoffmann-La Roche
Novartis